What Are the Benefits of Taking Tavneos? A Targeted Approach for Vasculitis
•
5 min read
In a pivotal clinical trial, 65.7% of participants treated with Tavneos achieved sustained remission of ANCA-associated vasculitis symptoms at 52 weeks, a significantly higher rate than the standard treatment arm. For adults managing severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), understanding what are the benefits of taking Tavneos is crucial for considering this targeted therapy.
